Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer
Cancer test maker Veracyte to pay $70 million upfront for C2i Genomics - San Francisco Business Times
Marc Stapley - CEO at Veracyte | The Org
Glaukos - Investors - Governance & Sustainability - Board of Directors - Person Details
Marc Stapley — Chief Administrative Officer and Executive Vice President at Illumina | Comparably
Veracyte, Inc. | LinkedIn
Illumina: Unidentified Financing Operation? - by Mike
Veracyte and Illumina partner to develop IVD tests
Marc Stapley - CEO at Veracyte | The Org
Marc Stapley Net Worth (2023) - GuruFocus.com
n2779_x119-img003.jpg
Illumina Executive Team | Comparably
Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO
Flatley Named Executive Chairman of Illumina as deSouza Steps Up to CEO Role | GenomeWeb
Marc Stapley - Veracyte
OncoCell MDx Appoints Marc Stapley to its Board of Directors | Business Wire
How could the STAMPEDE trial shape prostate cancer care? - Oncology Central
n2779_x119-img002.jpg
Veracyte Announces In Vitro Diagnostic Agreement With Illumina | Technology Networks
US genomics giant Illumina building new European HQ in Cambridge with 500 jobs | Business Weekly | Technology News | Business news | Cambridge and the East of England
1 Huge Reason to Buy Illumina, Inc. Stock Now | The Motley Fool
3 Things to Expect in Illumina's Q3 Earnings Results | The Motley Fool
With new CEO, Veracyte outlines €260M deal for French test maker HalioDx and global cancer testing expansion | Fierce Biotech
